<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1016">
  <stage>Registered</stage>
  <submitdate>12/12/2005</submitdate>
  <approvaldate>12/12/2005</approvaldate>
  <nctid>NCT00264914</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion</studytitle>
    <scientifictitle>An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion</scientifictitle>
    <utrn />
    <trialacronym>SIADH Safety</trialacronym>
    <secondaryid>LTS10208</secondaryid>
    <secondaryid>SFY5904</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Inappropriate ADH Syndrome</healthcondition>
    <healthcondition>Hyponatremia</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SR121463B

Treatment: drugs: SR121463B


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum sodium</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients aged 18 years and higher.

          -  SIADH (the diagnosis of SIADH is based on several criteria including true serum
             hypoosmolality, inappropriate urinary osmolality, clinical euvolemia, elevated urinary
             sodium excretion while on normal salt and water intake, and normal renal, adrenal, and
             thyroid functions: drug induced SIADH will be limited to carbamazepine or derivatives
             and antidepressants in patients in whom these drugs cannot be discontinued or easily
             replaced by other drugs)

          -  Serum sodium between 115 and 132 mmol/L (at least two consecutive serum sodium levels
             of at least 24 hours apart, from Day -6 to Day -1); for sodium levels between 125 and
             132 mmol/L, the spontaneous serum sodium increase between the two assessments on Day
             -1 should be &lt; 4 mmol/L

          -  Urinary osmolality &gt;200mOsm/kg H2O

          -  Urinary sodium &gt; 30 mmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with acute postoperative SIADH

          -  Presence of dilutional hyponatremia in hypervolemic states such as congestive heart
             failure and liver disease with ascites

          -  Presence of signs of hypovolemia (e.g., orthostatic hypotension, increased serum urea
             nitrogen, increased serum albumin, increased hematocrit, )

          -  Administration of other V2 receptor antagonists or demeclocycline or lithium within
             one month, thiazides diuretics or spironolactone within 15 days, and urea or loop
             diuretics within two days prior to study drug administration

          -  Patients with known treated or untreated adrenal deficiency

          -  Presence of untreated hypothyroidism

          -  Presence of uncontrolled diabetes with fasting glycemia &gt; 200 mg/dL (&gt; 11.09 mmol/L)

          -  Presence of clinical and/or electrocardiographical signs of acute myocardial
             infarction or acute ischemia, or any other clinically significant abnormality
             according to the Investigator on a 12 lead ECG recording

          -  Administration of inducers of CYP3A4 (phenytoin, rifampin, Saint John's Wort) or
             potent and moderate inhibitor so CYP3A4within two weeks prior to study drug
             administration

          -  Inadequate hematological, renal and hepatic functions; hemoglobin (Hb) &lt; 9 g/dL,
             neutrophils &lt; 1,500/mm3, platelets &lt;100,00/mm3, serum creatine &gt;175 Âµmol/L (or
             clearance of creatine &lt;30mL/min for where Ethics Committees require this parameter),
             ALT and /or AST &gt;2x upper limit of normal

          -  QTcB &gt; 500 ms

          -  Serum potassium &gt; 5 mmol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>57</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the long-term safety and tolerability of SR121463B in patients with syndrome of
      inappropriate antidiuretic secretion (SIADH). To assess the long-term efficacy of SR121463B
      in maintaining normal levels of serum sodium in patients with SIADH.

      Long term safety is evaluated further in an open label extension study with flexible doses of
      satavaptan.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00264914</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>